Skip to main content

Advertisement

Table 3 Variance of continuous CTC-counts according to therapy response after four (q4) or ten cycles (q10) of docetaxel

From: Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients

Response CTC-Detection Radiographic evaluation Clinical criteria
q0a q1a q4 q10 q0a q1a q4 q10
non-PD Median, Range 5 1 0 0 4.5 1 0 0
0-225 0-85 0-115 0-73 0-97 0-38 0-29 0-71
Patients, n= 25 25 25 17 24 24 24 14
PD Median, Range 24 9.5 32 23 22 11 34 17
4-97 1-58 3-358 0-36 4-225 1-85 3-358 0-73
Patients, n= 8 8 8 6 9 9 9 9
Significance, p= 0.04 0.01 <0.001 0.03 0.03 0.004 <0.001 0.03
  1. PD, progressive disease according to therapy response assessment at q4 or q10; q, cycle of docetaxel
  2. aCTC-variance was assessed as a function of objective response at q4